PUMA BIOTECHNOLOGY, INC.
Datakwaliteit: 100%
PBYI
NASDAQ
Manufacturing
Chemicals
€ 7,24
▼
€ 0,24
(-3,21%)
6 months return
—
Momentum
Neutral
5Y revenue growth
-2,54%
Groei
Revenue Growth (5Y)
-2,54%
Onder sectorgemiddelde (1,82%)
Revenue (1Y)-0,91%
Earnings (1Y)2,75%
FCF Growth (3Y)24,62%
Kwaliteit
Return on Equity
28,28%
Boven sectorgemiddelde (-54,47%)
ROIC27,49%
Net Margin13,62%
Op. Margin16,33%
Veiligheid
Debt / Equity
0,30
Onder sectorgemiddelde (0,30)
Current Ratio1,74
Interest Coverage5,63
Waardering
PE (TTM|NTM|2027)
12,61 | 11,51 | 11,86
Boven sectorgemiddelde (-1,50)
P/B Ratio3,40
EV/EBITDA7,73
Dividend YieldN/A
Quick Summary
Key Takeaways
Short bullets derived from reported financials—not the AI summary above.
Revenue declined -2,54% annually over 5 years
ROE of 28,28% indicates high profitability
Debt/Equity of 0,30 — conservative balance sheet
Generating 41,73 M in free cash flow
P/E of 12,61 — trading at a low valuation
Cash machine — converts 134,14% of earnings into free cash flow
Price History
Financiële Trends
Koersdoel Analisten
1 analist
Hold
-30.9%
upside to target
Huidig
€ 7,24
Consensus Target
€ 5,00
€ 5,00
Laag
€ 5,00
Hoog
Vooruitzicht
Forward K/W
11,51
Forward WPA
€ 0,65
WPA Groei (sch.)
+62,5%
Omzet Sch.
218,00 M
Winstverassingen
EPS
Reported
Estimate
Forecast
Next: Q1 2026
·
EPS Est: -€ 0,13
·
Rev Est: 42,00 M
| Q12025 | Q22025 | Q32025 | Q42025 | Q1 '26 | Q2 '26 | |
|---|---|---|---|---|---|---|
| Reported | € 0,10 | € 0,15 | € 0,21 | € 0,29 | — | — |
| Estimate | € 0,03 | € 0,07 | € 0,09 | € 0,23 | -€ 0,13 | € 0,07 |
| Verrassing | +300,00% | +114,29% | +133,33% | +26,09% | — | — |
Growth
Rev 5Y: -2,54% · Earnings 1Y: 2,75%
Growth
Rev 5Y: -2,54% · Earnings 1Y: 2,75%| Revenue Growth (1Y) | -0,91% | Revenue Growth (3Y) | -1,55% |
| Earnings Growth (1Y) | 2,75% | Earnings Growth (3Y) | 20,04% |
| Revenue Growth (5Y) | -2,54% | Earnings Growth (5Y) | N/A |
Profitability
ROE: 28,28% · Net Margin: 13,62%
Profitability
ROE: 28,28% · Net Margin: 13,62%| Revenue (TTM) | 228,37 M | Net Income (TTM) | 31,11 M |
| ROE | 28,28% | ROA | 15,64% |
| Gross Margin | N/A | Operating Margin | 16,33% |
| Net Margin | 13,62% | Free Cash Flow (TTM) | 41,73 M |
| ROIC | 27,49% | FCF Growth (3Y) | 24,62% |
Safety
D/E: 0,30 · Current: 1,74
Safety
D/E: 0,30 · Current: 1,74| Debt / Equity | 0,30 | Current Ratio | 1,74 |
| Interest Coverage | 5,63 | Asset Turnover | 1,15 |
| Working Capital | 60,85 M | Tangible Book Value | 115,27 M |
Dividends
Yield: N/A · Payout: N/A
Dividends
Yield: N/A · Payout: N/A| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
Valuation
P/E: 12,61 · EV/EBITDA: 7,73
Valuation
P/E: 12,61 · EV/EBITDA: 7,73| P/E Ratio | 12,61 | Forward P/E | 11,51 |
| P/B Ratio | 3,40 | P/S Ratio | 1,72 |
| PEG Ratio | N/A | Forward PEG | 0,18 |
| EV/EBITDA | 7,73 | Fwd EV/EBITDA | N/A |
| Forward P/S | 1,80 | Fwd Earnings Yield | 8,69% |
| FCF Yield | 10,64% | ||
| Market Cap | 392,26 M | Enterprise Value | 372,74 M |
Per Share
EPS: 0,61 · FCF/Share: 0,82
Per Share
EPS: 0,61 · FCF/Share: 0,82| EPS (Diluted TTM) | 0,61 | Revenue / Share | 4,49 |
| FCF / Share | 0,82 | OCF / Share | 0,82 |
| EPS CAGR (1Y) | -1,61% | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
Efficiency
FCF Conv: 134,14% · CapEx/Rev: 0,03%
Efficiency
FCF Conv: 134,14% · CapEx/Rev: 0,03%| CapEx / Revenue | 0,03% | FCF Conversion | 134,14% |
| SBC-Adj. FCF | 34,03 M | Growth Momentum | 1,63 |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 228,37 M | 230,47 M | 235,64 M | 228,03 M | 253,16 M |
| Net Income | 31,11 M | 30,28 M | 21,59 M | 2.000,0 | -29,13 M |
| EPS (Diluted) | 0,61 | 0,62 | 0,45 | 0,00 | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | 37,30 M | 30,97 M | 32,64 M | 23,72 M | 1,29 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | — | — | — | — | 71,87 M |
| SG&A Expenses | 70,85 M | 80,16 M | 89,93 M | 89,98 M | 116,29 M |
| D&A | 10,94 M | 11,52 M | 11,52 M | 8,92 M | 10,60 M |
| Interest Expense | 6,62 M | 12,45 M | 13,33 M | 11,59 M | 12,81 M |
| Income Tax | 4,67 M | -6,18 M | 1,08 M | 455.000,0 | 324.000,0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 216,30 M | 213,33 M | 230,53 M | 222,06 M | 226,59 M |
| Total Liabilities | 85,96 M | 121,21 M | 177,09 M | 200,45 M | 229,03 M |
| Shareholders' Equity | 130,34 M | 92,13 M | 53,44 M | 21,61 M | -2,45 M |
| Total Debt | 22,68 M | 68,00 M | 102,00 M | 102,00 M | 102,00 M |
| Cash & Equivalents | 29,64 M | 69,22 M | 84,59 M | 76,20 M | 63,13 M |
| Current Assets | 162,69 M | 147,66 M | 156,19 M | 134,28 M | 140,02 M |
| Current Liabilities | 81,25 M | 96,11 M | 99,38 M | 77,48 M | 109,59 M |
Sectorvergelijking
vs Manufacturing sector mediaan (1605 peers)
Vergeleken met vergelijkbare bedrijven in Manufacturing
Sectorvergelijking
vs Manufacturing sector mediaan (1605 peers) Vergeleken met vergelijkbare bedrijven in Manufacturing| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 12,6 | -1,5 |
| P/B | 3,4 | 1,6 |
| ROE % | 28,3 | -54,5 |
| Net Margin % | 13,6 | -41,5 |
| Rev Growth 5Y % | -2,5 | 1,8 |
| D/E | 0,3 | 0,3 |
ETFs Holding This Stock
ETFs Holding This Stock
{"event":"ticker_viewed","properties":{"ticker":"PBYI","listing_kind":"stock","pathname":"/stocks/pbyi","exchange":"NASDAQ","country":"US"}}